Nonsense mutations accelerate lung disease and decrease survival of cystic fibrosis children
- PMID: 37422433
- DOI: 10.1016/j.jcf.2023.06.005
Nonsense mutations accelerate lung disease and decrease survival of cystic fibrosis children
Abstract
Rationale: Limited information is available on the clinical status of people with Cystic Fibrosis (pwCF) carrying 2 nonsense mutations (PTC/PTC). The main objective of this study was to compare disease severity between pwCF PTC/PTC, compound heterozygous for F508del and PTC (F508del/PTC) and homozygous for F508del (F508del+/+).
Methods: Based on the European CF Society Patient Registry clinical data of pwCF living in high and middle income European and neighboring countries, PTC/PTC (n = 657) were compared with F508del+/+ (n = 21,317) and F508del/PTC(n = 4254).CFTR mRNA and protein activity levels were assessed in primary human nasal epithelial (HNE) cells sampled from 22 PTC/PTC pwCF.
Main results: As compared to F508del+/+ pwCF; both PTC/PTC and F508del/PTC pwCF exhibited a significantly faster rate of decline in Forced Expiratory Volume in 1 s (FEV1) from 7 years (-1.33 for F508del +/+, -1.59 for F508del/PTC; -1.65 for PTC/PTC, p < 0.001) until respectively 30 years (-1.05 for F508del +/+, -1.23 for PTC/PTC, p = 0.048) and 27 years (-1.12 for F508del +/+, -1.26 for F508del/PTC, p = 0.034). This resulted in lower FEV1 values in adulthood. Mortality of pediatric pwCF with one or two PTC alleles was significantly higher than their F508del homozygous pairs. Infection with Pseudomonas aeruginosa was more frequent in PTC/PTC versus F508del+/+ and F508del/PTC pwCF. CFTR activity in PTC/PTC pwCF's HNE cells ranged between 0% to 3% of the wild-type level.
Conclusions: Nonsense mutations decrease the survival and accelerate the course of respiratory disease in children and adolescents with Cystic Fibrosis.
Keywords: Cystic fibrosis (MeSH: DO008550); Cystic fibrosis transmembrane conductance regulator (MeSH: DO19005); Premature termination codon (MeSH: DO:18389).
Copyright © 2023. Published by Elsevier B.V.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2023 Nov 20;11:CD010966. doi: 10.1002/14651858.CD010966.pub4. PMID: 33331662 Free PMC article. Updated.
-
Functional Restoration of CFTR Nonsense Mutations in Intestinal Organoids.J Cyst Fibros. 2022 Mar;21(2):246-253. doi: 10.1016/j.jcf.2021.09.020. Epub 2021 Oct 17. J Cyst Fibros. 2022. PMID: 34666947
-
Cystic fibrosis in Europe: improved lung function and longevity - reasons for cautious optimism, but challenges remain.Eur Respir J. 2024 Mar 7;63(3):2301241. doi: 10.1183/13993003.01241-2023. Print 2024 Mar. Eur Respir J. 2024. PMID: 38302155 Free PMC article.
-
Geographic distribution and phenotype of European people with cystic fibrosis carrying A1006E mutation.Respir Med. 2022 Feb;192:106736. doi: 10.1016/j.rmed.2022.106736. Epub 2022 Jan 6. Respir Med. 2022. PMID: 35032736
-
Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.Cochrane Database Syst Rev. 2018 Aug 2;8(8):CD010966. doi: 10.1002/14651858.CD010966.pub2. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2020 Dec 17;12:CD010966. doi: 10.1002/14651858.CD010966.pub3. PMID: 30070364 Free PMC article. Updated. Review.
Cited by
-
Expanding the Impact of New Cystic Fibrosis Therapies in Low- and Middle-Income Countries.Pediatr Pulmonol. 2025 Mar;60 Suppl 1(Suppl 1):S90-S91. doi: 10.1002/ppul.27362. Epub 2024 Dec 3. Pediatr Pulmonol. 2025. PMID: 39625248 Free PMC article. Review.
-
Respiratory infections after elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis: analysis of the European Cystic Fibrosis Society Patient Registry.ERJ Open Res. 2025 Aug 4;11(4):01248-2024. doi: 10.1183/23120541.01248-2024. eCollection 2025 Jul. ERJ Open Res. 2025. PMID: 40761658 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials